Added to YB: 2025-12-30
Pitch date: 2025-12-29
ETON [bullish]
Eton Pharmaceuticals, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Market Cap
$451.3M
Pitch Price
N/A
Price Target
34.00 (+102%)
Dividend
N/A
EV/EBITDA
93.16
P/E
-65.04
EV/Sales
6.33
Sector
Pharmaceuticals
Category
growth
Show full summary:
The portfolio I am taking into 2026 - Eton Pharmaceuticals, Inc.
ETON: U.S. pharma applying Harrow playbook to ultra-rare diseases (IGF1 deficiency, pediatric adrenal insufficiency, Wilson's disease). $500M peak sales potential vs $451M mcap. Targeting profitability Q4/25, 30% revenue growth 2026/27. Trading 19x 2026 PE, 11x 2027 PE. Could double by end 2027.
Read full article (1 min)